Books about the pandemic. Books about the ancient past. Books about outer space. These were a few of Science News staff’s favorite reads. If your favorite didn’t make this year’s cut, let us know what we missed at feedback@sciencenews.org.
Vagina Obscura Rachel E. Gross W.W. Norton & Co. $30
For centuries, scientists (mostly males) have ignored female biology, and women’s health has suffered. But researchers are finally paying attention, as Gross explains in this fascinating tour of what little is known about female anatomy (SN: 4/9/22, p. 29).
The Song of the Cell Siddhartha Mukherjee Scribner $32.50
Patient stories and conversations with scientific luminaries enliven this tale of cell biology’s past, present and future, and how advances in the field have reshaped medicine (SN: 11/5/22, p. 28).
Breathless David Quammen Simon & Schuster $29.99
In this portrait of the coronavirus and the scientists who study it, Quammen investigates some of the most pressing questions about the pandemic, including whether or not the coronavirus could have accidentally escaped from a lab (SN: 9/24/22, p. 28).
Virology Joseph Osmundson W.W. Norton & Co. $16.95
This wide-ranging collection of essays is a meditation on society’s complicated relationship with viruses. In pondering SARS-CoV-2, HIV and more, Osmundson calls for more equitable access to medical care (SN: 7/16/22 & 7/30/22, p. 36).
The Milky Way Moiya McTier Grand Central Publishing $27
This absorbing “autobiography,” written from the perspective of the Milky Way (a very sassy Milky Way), draws on mythology and astronomy to persuade readers that our home galaxy deserves respect and admiration (SN: 9/10/22, p. 28).
A Portrait of the Scientist as a Young Woman Lindy Elkins-Tanton William Morrow $29.99
In this moving memoir, Elkins-Tanton recounts her journey to becoming a planetary scientist and leader of a NASA asteroid mission. Her struggles with childhood trauma and sexism in her career lay bare the barriers that many women in science still face (SN: 8/13/22, p. 26).
An Immense World Ed Yong Random House $30
So much of the world is beyond the grasp of human perception, but this safari through animal senses helps readers imagine what we’re missing (SN: 7/16/22 & 7/30/22, p. 36).
How Far the Light Reaches Sabrina Imbler Little, Brown, & Co. $27
By drawing parallels between their own life and the stories of bobbit worms, octopuses, sperm whales and other deep-sea dwellers, Imbler muses on such weighty themes as adaptation, survival and sexuality.
The Last Days of the Dinosaurs Riley Black St. Martin’s Press $28.99
The basic story of the downfall of nonbird dinosaurs is familiar: They were killed off by an asteroid that slammed into Earth 66 million years ago. Using the most up-to-date science, Black fleshes out this tale, painting a vivid portrait of life before and after this apocalypse (SN: 4/23/22, p. 28).
The Rise and Reign of the Mammals Steve Brusatte Mariner Books $29.99
The perfect follow-up to Black’s book on how the Age of Dinosaurs ended is this sweeping history of how the Age of Mammals began. Brusatte traces the origins of the evolutionary innovations that have made mammals so successful (SN: 6/18/22, p. 28).
Origin Jennifer Raff Twelve $30
Exactly how and when humans first came to the Americas is still unsettled science. But Raff gathers archaeological and genetic evidence to piece together a convincing scenario. She also points out past mistreatment of Indigenous communities by geneticists and calls on researchers to do better and foster more collaborations (SN: 2/12/22, p. 29).
Pests Bethany Brookshire Ecco $28.99
So-called pests are a human invention, argues Brookshire, a former staff writer for Science News for Students (now Science News Explores). In coming face to face with rats, feral cats, pythons and even elephants, Brookshire teases out the various social factors that cause people to deem certain animals a nuisance (SN: 12/3/22, p. 26).
A parasite might be driving some wolves to lead or go solo.
Wolves in Yellowstone National Park infected with Toxoplasma gondii make more daring decisions than their uninfected counterparts, researchers report November 24 in Communications Biology. The wolves’ enhanced risk-taking means they are more likely to leave their pack, or become leaders of their own.
“Those are two decisions that can really benefit wolves, or could cause wolves to die,” says Connor Meyer, a field biologist at the University of Montana in Missoula. The findings reveal a parasite’s potent ability to influence a wolf’s social fate.
Disease is often considered important for wildlife, mostly in the context of killing its host, Meyer says. “We have evidence now that just being infected with a certain parasite — Toxoplasma — can have pretty major implications for wolf behavior.” Single-celled T. gondii has a track record of altering animal behavior. Its most important hosts are cats, which provide a breeding ground for the parasite in their small intestine. The parasite offspring hitch a ride on feline feces. Other animals then ingest the parasite, which then manipulates its new hosts’ behavior by tweaking certain hormones, making the hosts bolder or more aggressive. Infected mice, for example, can fatally lose their fear of cats, allowing the parasite to infect more hosts once the mice are consumed (SN: 1/14/20).
In Yellowstone National Park, many wolves are also infected with T. gondii, recent research has shown. So Meyer and colleagues wondered if gray wolves (Canis lupus) in the park showed any parasite mind-bending of their own. Wolves were reintroduced to Yellowstone in 1995. Ongoing study of the park’s packs meant that the researchers had access to about 26 years’ worth of blood samples, behavioral observations and movement data for 229 of the park’s wolves.
The team screened the wolf blood for antibodies against T. gondii parasites, which reveal an infection. The researchers also noted which wolves left their pack — usually a family unit consisting of a breeding pair and their offspring — or became a pack leader.
Both are high-stakes moves for a wolf, Meyer says.
Infected wolves were 11 times as likely as noninfected wolves to disperse from their pack, the team found, and about 46 times as likely to eventually become leaders. The findings fit in with T. gondii’s apparent ability to boost boldness across a wide range of warm-blooded life. The study fills a crucial gap in the Toxoplasma pool of knowledge, says Ajai Vyas, a neurobiologist at Nanyang Technological University in Singapore, who was not involved with the study.
“Most of the earlier work has been done in the lab,” Vyas says. But there are limitations to that approach, especially for re-creating how animals experience the effects of the parasite in their natural environment. Such research has “become almost like studying whale swimming behavior in backyard pools; [it] does not work very well.”
Wolves’ enhanced boldness may even form a feedback loop, the team proposes. The researchers found that not only do cougars (Puma concolor) in the park carry the parasite, but wolves’ infection rates were highest when the animals’ ranges overlapped with the park’s densest aggregations of cougars. Infected wolf leaders may be more likely to bring pack members into riskier situations, including approaching cougar territories, making additional infections more likely.
The feedback-loop idea is “very fascinating,” but more research is needed to confirm it, says Greg Milne, an epidemiologist at the Royal Veterinary College in London, who was not involved with the study. Such research may involve determining if infected wolves are more likely to migrate into an area with more cougars.
“I think people are just starting to really appreciate that personality differences in animals are a major consideration in behavior,” says study coauthor Kira Cassidy, a wildlife biologist at the Yellowstone Wolf Project in Bozeman, Mont. “Now we add a parasite-impacting behavior to the list.”
Next, the team is interested in examining the long-term consequences of a T. gondii infection, and whether infected wolves make better leaders or dispersers than uninfected wolves.
It’s also not known how infection impacts survival and reproduction rates, Cassidy says. “Infection may very well be detrimental in some ways and advantageous in others.”
As we head into our third pandemic winter, most people are all too familiar with the signs of COVID-19. The disease wears many different faces and can show up as chills, cough, difficulty breathing or other troublesome jumbles of symptoms. But sometimes, this illness can look positively peculiar.
On rare occasions, SARS-CoV-2 rears its head in body parts not typically touched by respiratory viruses. From head to COVID toe, doctors have seen a bevy of bizarre cases. Patchy tongues, puffy digits, hair loss — such issues can be worrisome for patients, says Peter Chin-Hong, an infectious diseases physician at the University of California, San Francisco.
But the outlook doesn’t have to be. That’s because such symptoms can end up going away on their own, says Chin-Hong, who has treated hundreds of people with COVID-19.
No one knows exactly how often COVID tongue, COVID toe, COVID eye or other rare conditions occur — and it’s not always clear that COVID-19 is the actual culprit. Still, the sheer scale of coronavirus infections means that SARS-CoV-2 has had many chances to show its stuff (SN: 9/8/22). The United States is now closing in on 98 million confirmed cases. Such a staggering case count means that “statistically speaking, you’re going to find people with more and more weird things,” Chin-Hong says. Doctors rely on medical case reports for leads on potential treatments and hints about how long symptoms may last. Even just knowing that someone else has had splotchy mouth sores or tender toes can be helpful, Chin-Hong says. That lets him tell his patients, “You’re not the only one,” he says. “That means a lot to a lot of people.”
Internal medicine doctor Saira Chaughtai published one such study in October in the Journal of Medical Case Reports after one of her primary care patients came in with a symptom Chaughtai had never seen. Ten days after testing positive for COVID-19, the patient’s tongue began to swell, eventually erupting in white-ringed lesions.
Certain spots looked “denuded,” says Chaughtai, of Hackensack Meridian Health in Neptune, N.J. It was as if some of the tongue’s surface bumps had been sandpapered away. The patient wasn’t someone doctors would typically consider vulnerable, either. She was 30 years old, fit and healthy.
“I was like, ‘Oh my god, COVID can do anything,’” Chaughtai remembers thinking. Oral sores can look different among patients. Chin-Hong has seen people with tongues coated white, as if they’d chewed a mouthful of tortilla chips. For Chaughtai’s patient, COVID tongue felt sensitive and irritated, with flare-ups that burned. Chaughtai wasn’t sure how to treat it.
She searched the scientific literature and prescribed an assortment of mouthwashes, which helped. But six months in, the patient’s tongue hadn’t fully healed. So Chaughtai got creative. She teamed up with a sports medicine doctor, who beamed low-level laser light at the patient’s tongue. He had previously used this photobiomodulation therapy to treat muscle injuries.
Laser light therapy makes blood vessels dilate, enhancing blood flow to treated areas, which could promote healing, Chaughtai says. It seemed to work for her patient. The tongue lesions began to heal and flare-ups subsided. The woman still occasionally feels some tongue sensitivity when stressed, but never as bad as her initial outbreak.
The effects of COVID toe About 1,300 kilometers west, a podiatrist in Crown Point, Ind., also dilated a patient’s blood vessels to treat a curious coronavirus condition: COVID toe. After infection with SARS-CoV-2, patients’ fingers and toes can plump up, sometimes painfully, and turn pink or reddish purple.
“We were seeing cases of these lesions that look like chilblains, which is something you get when you’re exposed to cold weather,” says Michael Nirenberg of Friendly Foot Care. But his patients hadn’t been in the cold — they’d been exposed to the coronavirus.
Nirenberg has seen as many as 40 people with the symptom, which he’s found tends to clear up in a month or two. But one of his patients, a 59-year-old man, just couldn’t kick COVID toe. It ultimately lingered for nearly 670 days — the longest documented case Nirenberg has seen. “The term we used was long COVID toe,” he says. Nirenberg and colleagues reported the case this spring in the Journal of Cutaneous Pathology. Nirenberg prescribed daily application of a nitroglycerin ointment to boost blood flow to the toes. That may have helped, Nirenberg says, “but I don’t know if time also did the trick.” After 22 months, the condition may have finally resolved on its own.
The number of COVID toes Nirenberg encounters these days has gone down, but he’s still seeing people come in with the condition. And though Chaughtai has not treated another case of COVID tongue, a man recently e-mailed her saying that he had suffered from a similar affliction for two years.
UCSF’s Chin-Hong says he thinks it’s important for people to know that COVID-19 can cause such a variety of symptoms (SN: 11/11/22). “We can’t really predict who’s going to get what,” he says. But in his experience, strange symptoms have tended to crop up more often in people who haven’t been vaccinated.
Such symptoms may not be as serious as COVID-affected hearts or lungs, but they can certainly look scary, Chin-Hong says. “If this is a reason why some people might get vaccinated,” he says, “I think that would be great.”
If you saw Carlos Argüelles-Delgado’s childhood bedroom — the whiteboard for working out problems, the math textbooks they asked for as birthday gifts — you’d likely not be surprised that this kid would grow up to push the boundaries of modern physics.
For years, physicists have known that the most successful theory to describe what the universe is made of, called the standard model, is broken. By prying at one of the biggest cracks in the framework — neutrinos — Argüelles aims to discover what’s next for the field.
Neutrinos are mysterious even for subatomic particles. They’re hard to study because they barely interact with matter, and what scientists do know about them is baffling — like the fact that neutrinos have mass when the standard model predicts they shouldn’t. “That’s why I like neutrinos,” Argüelles says. “They misbehave.”
Many scientists think this confusing behavior is a sign that neutrinos are affected by undiscovered particles. In that case, demystifying neutrinos could open a new window on the universe. The question is: Who are these hidden partners, and how can scientists find them? Standout research To search for answers, Argüelles often relies on data from the IceCube Neutrino Observatory in Antarctica. IceCube’s thousands of buried detectors spot neutrinos from the faint flashes of light they leave after interacting with ice.
For their Ph.D., Argüelles combed through these signals to look for “sterile” neutrinos. If this breed of neutrinos exists, they would interact with matter even less than normal neutrinos do. Sterile neutrinos could explain several troubling problems with the standard model, like why neutrinos have mass and why antimatter is rarer than matter. Sterile neutrinos are also a candidate for dark matter, the unidentified substance that outweighs normal matter in the universe.
The search made for a huge project, but Argüelles finished it in about half of the time typical for U.S. Ph.D.s in the physical sciences. And though they found no signs of the would-be particle, Argüelles ruled out some ideas about what it could be like. “It was an amazing performance,” says neutrino physicist Francis Halzen, who advised Argüelles’ Ph.D. work at the University of Wisconsin–Madison and is IceCube’s head scientist. “It was a piece of art.”
Argüelles also looks for other possible hidden particles, like WIMPs, a hypothetical particle that could be a form of dark matter. And Argüelles isn’t afraid to pursue research farther from their specialty. Though no expert in quantum computers, for example, Argüelles was the first to use a quantum computer to simulate how neutrinos can change from one type to another. That could one day help scientists better understand neutrino-rich events like supernova explosions.
“I just hate when people tell me I cannot do something,” Argüelles says.
Halzen describes Argüelles as fearless, the kind of scientist who is never afraid to ask questions. “I don’t think they have any regard for their reputation, ever,” he says. Backstory Argüelles’ attitude toward research is, in part, forged by past struggles to overcome hardship and discrimination.
“There are worse things in life than not being able to solve a problem,” they say.
Growing up in Peru meant building a life on shifting ground. The economy was unstable, and at times Argüelles’ family struggled to make ends meet.
Though Argüelles’ parents were supportive and saw knowledge as a safe investment, they at first rejected Argüelles’ desire to study physics. Argüelles, wiping a tear from their eye, recalls their father saying, “You’re just going to die of hunger.” Soon Argüelles’ parents did embrace the career choice.
Argüelles says Peru, when they were growing up, was also an “extremely negative environment” for LGBTQ+ people. “I’m a gay man,” they say, “and it was very, very, very difficult.”
Same-sex marriages are not recognized in Peru. Hate crimes and discrimination based on sexual orientation were only prohibited in 2017, by a presidential decree that the country’s Congress tried but failed to overturn.
When Argüelles left Peru in 2012 to pursue their Ph.D., they found that studying physics in the United States wasn’t without obstacles. Almost nobody high up in the field looked like them. They struggled under the weight of expectations and felt that voicing their anxieties would get them branded as weak. But with help from mentors, Argüelles persevered.
Now, as an assistant professor at Harvard, Argüelles sees their students — particularly women and Hispanics — facing the same challenges. Argüelles is passionate about supporting them.
“It’s about not giving up, right?” Argüelles says. “I still go through some of these things myself. But I’ll survive it.”
Visitors to the village of Drumnadrochit, on the western shore of Scotland’s murky Loch Ness, come to see the nearby ruins of Urquhart Castle or to chance a glimpse of the elusive Loch Ness Monster. But growing up in Drumnadrochit, planetary scientist Robin Wordsworth says it was the unobscured view of the cosmos that seized his attention. “There are incredibly clear skies up there,” he says.
Today, Wordsworth lives on the other side of the Atlantic. He’s a researcher and professor at Harvard University. But his gaze is still set on the solar system and beyond. From studying how rocky planets may occasionally become encased in glaciers to exploring the sizes of alien raindrops or the details of how humans might one day settle Mars, Wordsworth’s scientific explorations vary widely. His research group tends to “do a lot of different things at once,” he says. “If I was to summarize it in a sentence, it would be to understand what drives habitability on planets through time.”
Standout research Wordsworth defines a planet’s habitability as its ability to support life. The idea that life could survive elsewhere in the cosmos has always fascinated Wordsworth, a science fiction fan. Apart from Earth, astronomers have discovered roughly 20 potentially habitable worlds in the universe. With data collected by ground-based observatories, satellites and rovers, he uses supercomputers to construct simulations of planets and the evolution of their climates. Climate is a big focus because it determines whether a planet’s surface can harbor liquid water — a necessity for all known forms of life. Wordsworth’s most notable research reconstructs the climate of early Mars. Martian river valleys and other geologic clues suggest that abundant liquid water once flowed across the Red Planet, and the early Martian climate has thus become a hot topic for scientists seeking signs of alien life. But for decades, the best researchers could do was build one-dimensional models that struggled to replicate key atmospheric components, such as clouds.
In 2013 while at the Laboratory of Dynamic Meteorology in Paris, Wordsworth and colleagues presented a 3-D model of the early Martian climate, with clouds and an atmosphere containing large amounts of carbon dioxide. Those are key components for studying how the early Martian atmosphere may have reflected and trapped heat, says astrobiologist James Kasting of Penn State.
Wordsworth was the one who figured out how to incorporate clouds into the model, thanks to his strong programming skills, handle over mathematics and determination, Kasting says. “He’s been publishing the best climate calculations for early Mars. There’s really nobody else who is in his lane.” What’s next Wordsworth’s otherworldly reconstructions may help us better understand whether life might have emerged on Mars or elsewhere. Another strand of his research could help humans one day settle the Red Planet.
Today, most of Mars’ surface is too cold to sustain liquid water, and the planet’s thin atmosphere offers little protection from the sun’s intense ultraviolet radiation. These conditions make it inhospitable to would-be Martian settlers. But in a 2019 study, Wordsworth and colleagues proposed that sheets of insulating silica aerogel deployed over ice-covered areas might make survival possible.
In lab tests, layers of aerogel just centimeters thick filtered out 60 percent of UVA and UVB radiation and almost all of the more dangerous UVC rays, while permitting enough light through for photosynthesis. What’s more, the shields warmed the air underneath by more than 50 degrees Celsius, which could make liquid water and growing crops possible. Looking ahead, Wordsworth plans to investigate how settlers on Mars might use bioplastics or other renewable materials to become self-sustaining.
And far beyond the Red Planet, the exoplanets await. “The James Webb Space Telescope has just begun to collect new exoplanet data,” Wordsworth says. Observations of their atmospheres will help researchers test ideas about how these distant planets and their climates evolve, he says. “It’s just an incredibly exciting time.”
Belinda Hankins first grappled with COVID-19 in the spring of 2020. She had a fever, chills and trouble breathing, but the real clincher was her loss of smell. Hankins remembers opening a canister of Tony Chachere’s creole seasoning, lowering her nose to take a whiff, and not smelling a thing. “That stuff usually clears the kitchen,” she says.
Her second infection, two years later, was worse. After 12 long weeks of endless fatigue and aching joints, her doctor suggested she seek treatment for long COVID. The lingering, sometimes full-body condition can plague people for months or years after a COVID-19 infection (SN Online: 7/29/22).
In late August, I joined Hankins, age 64, in a small exam room for her first in-person consultation at the Johns Hopkins Post-Acute COVID-19 Team clinic. Wearing a navy dress and a blue surgical mask, Hankins is sitting in a chair across from physician Alba Azola. As they discuss Hankins’ symptoms, doctor and patient face each other, Azola occasionally swiveling her stool to tap notes into a computer.
Hankins’ symptoms are extensive. Brain fog, fatigue and pain top the list. She’s depressed. Sleep doesn’t feel restful. She has trouble focusing, is often light-headed and regularly loses her balance. Even walking to the clinic from the parking lot left her winded and in pain. “I’m extremely exhausted,” she says. “I have not felt good in a long time.” Hankins, pauses, wiping away a tear. “I wasn’t like this before.” Hankins, a retired digital media consultant, used to be an avid skier and a cyclist. She loved to travel and dance and was planning to learn how to play golf. She’s not sure what the future holds, though she tells me she still has faith she can be active again.
Treating people with long COVID can be complicated – especially for Hankins and those who have other medical conditions. She has pulmonary hypertension, fibromyalgia and the connective tissue disease scleroderma. It’s tricky to tease out which symptoms come from the viral infection. Azola’s approach is to listen, ask questions and listen some more. Then, she’ll zero in on a patient’s most pressing concerns. Her goal: manage their symptoms. “How can we make their quality of life better?” she asks. System overload On the afternoon of Hankins’ visit, it’s a warm summer day in Baltimore, blue skies laden with fleecy clouds. Inside the labyrinthine halls of Johns Hopkins Bayview Medical Center, the vibe is not quite as sunny: bright lights, shiny floors, people in line and people in scrubs. Everyone I see is masked.
Azola meets me in the waiting area, walking briskly and wearing bright red glasses. Before the pandemic, Azola, a rehabilitation physician, treated patients recovering from strokes, spinal cord injuries and other disorders. Most mornings, she still works with these patients. But for the past two years, her afternoons have been booked with people laid low by COVID-19.
She’s squeezed me in to talk about the Johns Hopkins PACT clinic, which opened in April 2020, around the time when the world hit one million confirmed cases. “To be honest, we didn’t know what to expect,” Azola says. Back then, most of the clinic’s patients were recovering from COVID-19 after a stay in the hospital’s intensive care unit. Now, at least half of their patients never got sick enough with COVID-19 to be hospitalized – yet still had symptoms they couldn’t shake. In a single week, Azola and her colleagues may get 30 referrals. “It’s constant,” she says, “more than we can provide service to.”
As those referrals pile up, patient wait times can stretch. The PACT clinic expanded last summer, and now has more than a dozen people on staff, including therapists, physicians and other specialists. They try to keep the wait to around two months, Azola says, but sometimes it takes up to four months for a patient to be seen. The demand here and at clinics across the country isn’t likely to let up. As of mid-November, the United States has reported nearly 97.9 million cases of COVID-19. Though long COVID numbers can be hard to pin down, nearly half of people infected with SARS-CoV-2 hadn’t fully recovered six to 18 months after their infection, according to a large Scottish study published in Nature Communications on October 12. A more conservative estimate from the United States suggests that more than 18 million U.S. adults could have long COVID.
“We are in the middle of a mass disabling event,” says Talya Fleming, a physician at the JFK Johnson Rehabilitation Institute in Edison, N.J.
Scattershot solutions In the United States, some 400 clinics have popped up from coast-to-coast to care for the growing wave of long COVID patients.
Although the American Academy of Physical Medicine and Rehabilitation has published some guidance, no gold-standard therapies exist and there are no formal criteria for long COVID clinic performance. The Academy brought together more than 40 post-COVID clinics, including the Hopkins PACT clinic, to share experiences and discuss best practices for long COVID treatment. “We’re kind of guiding each other,” Azola says. Other clinics in the United States are more-or-less forging their own paths.
Today, Azola and colleagues are focusing on their patients’ symptoms, a strategy other long COVID doctors and clinics are using too. “There is no one, singular long COVID experience,” says pulmonologist Lekshmi Santhosh. So doctors really need to take a “customized, symptom-directed approach.”
Santhosh founded the OPTIMAL clinic at the University of California, San Francisco to provide follow-up care for people who had COVID-19. Since 2020, she’s seen hundreds of patients, who can wait weeks to months for an appointment, like they do at Hopkins. One main question Santhosh hears from patients is: “When am I going to get better?” That’s hard to answer, she admits. Scientists can’t yet predict how or when a patient will recover, and they don’t know why long COVID strikes some people and spares others. Right now, there are no obvious rules. “If you are young, you can get long COVID. If you have no pre-existing health conditions, you can get long COVID. If you’ve had COVID before, you still can get long COVID,” Fleming says. The list goes on.
At UCSF, Santhosh says she’s seen it all. Long COVID can affect a 75-year-old patient who was hospitalized for COVID-19, or a 35-year-old marathoner whose stubborn symptoms developed after just a mild infection. One patient can be hit with a hailstorm of health conditions, another patient, just a few.
“I’ve heard some weird things,” Azola says. She remembers one patient who felt as if a phone were vibrating deep inside their bones. Another described a sensation of heaviness, like their legs were made of lead.
Long COVID’s scattershot symptoms currently require a smorgasbord of solutions. For headaches, a doctor might prescribe a combo of pain relievers. For shortness of breath, an inhaler to open the airways could help. For brain fog, patients might visit a therapist who can help them with word-finding issues. Such symptom management is necessary, Azola says, because “we don’t have strong, randomized controlled trials to support the use of specific medications or treatments,” she says.
Developing effective therapies has been “frustratingly slow,” Santhosh says. Scientists are still trying to understand what’s happening in the body that spurs long COVID and lets symptoms simmer away unchecked. “The underlying biology is unclear,” she says. That makes it “unclear exactly what treatments might work.”
Long COVID’s biological underpinnings are a hot topic among researchers today, says Mike VanElzakker, a neuroscientist at Harvard Medical School and Massachusetts General Hospital, and part of the Long COVID Research Initiative, a group working to study and treat the condition. Scientists have scads of hypotheses for what causes long COVID symptoms, including lungs scarred by SARS-CoV-2 or the reawakening of some other, long-slumbering virus. One idea posits that COVID-19 might sabotage the immune system, inviting other microbes to do harm. Another idea pins long COVID on caches of coronavirus hiding within the body’s tissues.
“It really does matter what’s causing these problems,” VanElzakker says. If doctors knew what’s driving a patient’s symptoms, they might be able to offer personalized treatments aimed at the illness’s root.
Filling the void On Facebook pages and websites around the internet, purported long COVID treatment options abound.
Vitamins, supplements, alternative medicines: general internist Aileen Chang in Washington, D.C. used to hear all the time from long COVID patients about therapies they’ve tried. In the fall of 2020, Chang and colleagues started the George Washington Medical Faculty Associates COVID-19 Recovery Clinic, which later closed its doors due to a staffing shortage. She recalls patients who flew to different countries to have their blood filtered and others who took “every sort of supplement you can imagine,” she says. “They’re looking for solutions.”
Without clear data on what long COVID treatments work, opportunists have stepped in to fill the void. Some unproven treatments may be scams with serious side effects; they can also drain patients financially. “They’re spending all this money on things they think will make them better,” Chang says, “but the truth is… we don’t know.”
What scientists do know is that potential long COVID treatments are still in their early days. There’s some evidence that getting a COVID-19 vaccine can improve long COVID patients’ symptoms, though this idea is still controversial, researchers reported in November in eClinicalMedicine. And repeated sessions of breathing 100 percent oxygen in a hyperbaric chamber might relieve fatigue and brain fog, small studies of patients have suggested. Last year, the U.S. National Institutes of Health launched a massive research project on the long-term effects of COVID-19. Called the RECOVER Initiative, the project aims to uncover why some people get long COVID and to identify underlying causes. As of November 11, RECOVER has enrolled 10,645 of an estimated 17,680 adults needed.
It’s a great initiative, Santhosh says, but it got rolling relatively late – well after long COVID had already upended many people’s lives. “We need… a lot more funding and a lot more therapeutic trials,” she says. Santhosh is hopeful that, in the coming months and years, doctors will have solid answers on what treatments actually work. “There are a lot of tantalizing biological leads,” she says. Though she knows that this timeframe can feel agonizingly long to patients and clinicians. Real life In the meantime, Santhosh, Azola and other physicians are borrowing strategies that help for other disorders – like myalgic encephalomyelitis/chronic fatigue syndrome. Many of the symptoms of that still-mysterious illness overlap with those of long COVID, a symmetry that could bring answers for both disorders, scientists suggest September 8 in Science.
One common approach isn’t a treatment like pills or surgery, it’s more of a shift in behavior: Don’t overdo it, Santhosh says. “We talk to our long COVID patients about this all the time, about the need to rest, to pace yourself and how to gently bring back your aerobic fitness.”
Long COVID patients with fatigue can be tempted to try and push through, to keep speeding through life as they had before their diagnosis. But that doesn’t seem to work for people with chronic fatigue, and “for some long COVID patients, it can actually make things worse,” she’s found.
Azola has similar advice for Hankins. About a half hour into the appointment, Azola slides away from the computer desk, and turns toward her patient. “This is the part where people want to punch me in the face,” she tells Hankins, pushing her glasses up onto her head. “We don’t have a magic wand that makes [you] feel better.”
Instead, Hankins will need to check her body’s battery every day, conserve energy where she can, and build in opportunities to recover. Little tricks, like sitting in a chair while showering or prepping food, can help patients save enough juice to make it through the day. Azola hopes to get Hankins off the “corona coaster,” where patients can feel relatively good one day, and the next day, crash. Having energy levels constantly crater can erode a patient’s ability to live their lives, she says. For the next 20 minutes, doctor and patient talk about how Hankins’ life has changed and what her next steps will be. In a week, she’ll meet with a neuropsychologist who will help her cope with her new reality; Azola also refers Hankins to a pain specialist.
The two women have spent about an hour together – a near-eternity for a medical appointment. For Azola, it’s time well spent. “The most important thing is to listen to patients and keep an open mind,” she says.
When I speak with Hankins nearly three weeks later, she’s still feeling hopeful. She’s met with the neuropsychologist, and will continue to receive follow-up care. For Hankins, a care plan that factors in all of her conditions, including long COVID, may one day let her feel like herself again.
For now, she’s hoping that sharing her story will help others struggling with the illness. When she tells people she has long COVID, she says, “some of them don’t even think it’s real.”
Late in the evening of February 28, 2021, a coal-dark space rock about the size of a soccer ball fell through the sky over northern England. The rock blazed in a dazzling, eight-second-long streak of light, split into fragments and sped toward the Earth. The largest piece went splat in the driveway of Rob and Cathryn Wilcock in the small, historic town of Winchcombe.
An analysis of those fragments now shows that the meteorite came from the outer solar system, and contains water that is chemically similar to Earth’s, scientists report November 16 in Science Advances. How Earth got its water remains one of science’s enduring mysteries. The new results support the idea that asteroids brought water to the young planet (SN: 5/6/15).
The Wilcocks were not the only ones who found pieces of the rock that fell that night. But they were the first. Bits of the Winchcombe meteorite were collected within 12 hours after they hit the ground, meaning they are relatively uncontaminated with earthly stuff, says planetary scientist Ashley King of London’s Natural History Museum. Other meteorites have been recovered after being tracked from space to the ground, but never so quickly (SN: 12/20/12).
“It’s as pristine as we’re going to get from a meteorite,” King says. “Other than it landing in the museum on my desk, or other than sending a spacecraft up there, we can’t really get them any quicker or more pristine.”
After collecting about 530 grams of meteorite from Winchcombe and other sites, including a sheep field in Scotland, King and colleagues threw a kitchen sink of lab techniques at the samples. The researchers polished the material, heated it and bombarded it with electrons, X-rays and lasers to figure out what elements and minerals it contained.
The team also analyzed video of the fireball from the UK Fireball Alliance, a collaboration of 16 meteor-watching cameras around the world, plus many more videos from doorbell and dashboard cameras. The films helped to determine the meteorite’s trajectory and where it originated.
The meteorite is a type of rare, carbon-rich rock called a carbonaceous chondrite, the team found. It came from an asteroid near the orbit of Jupiter, and got its start toward Earth around 300,000 years ago, a relatively short time for a trip through space, the researchers calculate.
Chemical analyses also revealed that the meteorite is about 11 percent water by weight, with the water locked in hydrated minerals. Some of the hydrogen in that water is actually deuterium, a heavy form of hydrogen, and the ratio of hydrogen to deuterium in the meteorite is similar to that of the Earth’s atmosphere. “It’s a good indication that water [on Earth] was coming from water-rich asteroids,” King says.
Researchers also found amino acids and other organic material in the meteorite pieces. “These are the building blocks for things like DNA,” King says. The pieces “don’t contain life, but they have the starting point for life locked up in them.” Further studies can help determine how those molecules formed in the asteroid that the meteorite came from, and how similar organic material could have been delivered to the early Earth.
“It’s always exciting to have access to material that can provide a new window into an early time and place in our solar system,” says planetary scientist Meenakshi Wadhwa of Arizona State University in Tempe, who was not involved in the study.
She hopes future studies will compare the samples of the Winchcombe meteorite to samples of asteroids Ryugu and Bennu, which were collected by spacecraft and sent back to Earth (SN: 1/15/19). Those asteroids are both closer to Earth than the main asteroid belt, where the Winchcombe meteorite came from. Comparing and contrasting all three samples will build a more complete picture of the early solar system’s makeup, and how it evolved into what we see today.
Radiation-tolerant microbes might be able to live beneath Mars’ surface for hundreds of millions of years and may yet persist today, thanks in part — counterintuitively — to the Red Planet’s frigid, arid conditions.
In addition to being cold and dry, the Martian surface is constantly bombarded by cosmic rays, charged particles and other radiation from space. Previous studies have shown that desiccation vastly extends a microbe’s potential for surviving by limiting the production of highly reactive oxygen-bearing chemicals that can damage proteins and DNA, among other vital molecules within its tissues. To see how long microbes might survive such an onslaught on Mars, researchers desiccated five species of bacteria and one type of yeast, stored them at −80° Celsius and then irradiated them.
Some of the microbes might remain viable for only a few tens of thousands of years, experiments showed. But one species — Deinococcus radiodurans, a particularly radiation-hardy greebly that some scientists have nicknamed “Conan the bacterium” — might survive for as long as 280 million years if protected from radiation at soil depths of 10 meters or more, physical chemist Brian Hoffman and colleagues report online October 25 in Astrobiology.
D. radiodurans resists radiation damage by having multiple copies of chromosomes and other genetic material in each cell, as well as high levels of manganese-bearing antioxidants that help remove DNA-damaging chemicals (SN: 9/3/10). If similar microbes evolved on Mars, they too could persist for lengthy intervals, even possibly until now — which is “improbable but not impossible,” says Hoffman, of Northwestern University in Evanston, Ill.
Even if microbes that evolved on Mars ultimately succumbed to the harsh conditions, remnants of their proteins or other macromolecules may remain — offering hope that future missions, if equipped with the proper equipment, might be able to detect those signs of former life.
In early 2022, malaria cases in the Ethiopian city of Dire Dawa surged, with more than 2,400 people sickened. The spike in infections was the work of an invasive mosquito species that’s spreading across Africa, scientists report.
The finding, presented November 1 in Seattle at the annual meeting of the American Society of Tropical Medicine and Hygiene, provides evidence that the invasive vector can drive malarial outbreaks. Worryingly, the species can thrive in urban environments, bringing the threat of malaria to potentially many millions more people across the continent.
Anopheles stephensi is a mosquito native to India and the Persian Gulf, where it is a major vector for the Plasmodium parasites that cause malaria in people (SN: 10/26/20). In Africa, the primary malaria vector is Anopheles gambiae. A. stephensi was first reported on the African continent in Djibouti in 2012. Since then, the species has turned up in other African countries such as Ethiopia, Somalia and Nigeria.
It wasn’t clear what kind of malarial burden the invasive mosquito could bring to Africa, says Fitsum Girma Tadesse, a molecular biologist at the Armauer Hansen Research Institute in Addis Ababa, Ethiopia. In the eight years after the mosquito’s arrival in Djibouti, the country reported a 40-fold increase in yearly malaria cases, Tadesse says. But no one had directly linked A. stephensi to the increase.
So when malaria cases suddenly rose in Dire Dawa — from 27 cases to 260 in just three weeks in early 2022 — Tadesse and his team jumped in to investigate.
The researchers tracked 80 patients in the city who had sought care for malaria at a local or university clinic, as well as 210 patients who had sought treatment for other reasons, and they screened the patients’ household members for malaria. The team also scanned the patients’ neighborhoods for the presence of mosquito adults and larvae within a 100-meter radius of households, or in the cases of students that visited a clinic, dormitories.
The team found that the malaria patients primarily lived near water sources used by the invasive mosquito, A. stephensi. Households and dorms close to aquatic habitats harboring A. stephensi larvae were 3.4 times as likely as those not close to such water sources to have a family or dorm member test positive for malaria. And most of the adult mosquitoes the team caught — 97 percent — were of the invasive species, the only mosquito species that the researchers found carrying Plasmodium parasites. A. stephensi “prefers to breed in water storage containers that are typically common in rapidly expanding urban settings,” Tadesse says. The native mosquito species, A. gambiae, tends to use natural sources of water like small pools, which are more common in rural regions, he adds. The concern, then, is that with the expansion of A. stephensi alongside urbanization in Africa, the mosquito could exploit many new sources of water stores.
“This expands the malaria problem from a predominantly rural problem to an urban problem,” says Teun Bousema, an epidemiologist at Radboud University in Nijmegen, the Netherlands.
A 2020 study from another research group estimated that if the invasive mosquito were to spread widely on the continent, an additional 126 million people in cities could be at risk of contracting malaria.
“The spread of Anopheles stephensi is concerning because this species has a number of characteristics that make it difficult to control,” says Tanya Russell, a medical entomologist at James Cook University in Townsville, Australia, who was not involved in the study. Not only can the insects lay their eggs in nearly any available water source, but also the eggs can survive being dry for long periods of time. “This is very uncharacteristic for malaria vectors.”
Insecticide-treated bed nets and spraying a residual insecticide indoors are the primary vector control approaches for malaria-carrying mosquitoes, Russell says. But since A. stephensi also bites outdoors, the mosquito’s spread may blunt the efficacy of these tools.
The key next steps, Tadesse says, are interventions to reduce transmission of the deadly parasites, including targeting the mosquito’s larval phase with chemicals and encouraging communities to cover and secure water containers to prevent mosquitoes from laying eggs in them.
“The window of opportunity to do something about this species is closing,” Bousema says. “So, I really think this calls for very urgent action.”
To coax human nerve cells in a laboratory to thrive, there are three magic words: location, location, location.
Many experiments grow human nerve cells in lab dishes. But a new study enlists some real estate that’s a bit more unconventional: the brain of a rat. Implanted clusters of human neurons grow bigger and more complex than their cohorts grown in dishes, researchers report online October 12 in Nature.
Not only that, but the human cells also appear functional, albeit in very limited ways. The implanted human cells can both receive signals from rat cells and influence the rats’ behavior, connections that “demonstrate more substantial integration of the transplanted neurons,” says Arnold Kriegstein, a developmental neuroscientist at the University of California, San Francisco, who wasn’t involved in the study. “This is a significant advance.”
Over the last decade, scientists have been building increasingly complex brain organoids, 3-D clusters of cells derived from stem cells that grow and mimic the human brain (SN: 2/20/18). These organoids don’t re-create the full complexity of human neurons that develop in an actual brain. But they can be windows into an otherwise inscrutable process — human brain development, and how it can go awry (SN: 9/3/21). “Even if they’re not entirely perfect, [these models] are surrogates for human cells in a way that animal cells are not,” Kriegstein says. “And that’s really exciting.”
To push these cells closer to their full potential, Sergiu Pasca, a neuroscientist at the Stanford School of Medicine, and colleagues surgically implanted human cerebral organoids into the brains of newborn rat pups. Along with their hosts, the human organoids began to grow. Three months later, the organoids were about nine times their starting volume, ultimately making up about a third of one side of the rat’s cortex, the outer layer of the brain. “It pushes the rat cells aside,” Pasca says. “It grows as a unit.”
These human cells flourished because rats’ brains offer perks that lab dishes can’t, such as blood supply, a precise mix of nutrients and stimulation from nearby cells. This environmental support coaxed individual human neurons to grow bigger — six times as large by one measure — than the same sort of cells grown in dishes. Cells grown in the rat brains were also more complex, with more elaborate branching patterns and more cell connections called synapses. The cells looked more mature, but Pasca and his colleagues wanted to know if the neurons would behave that way, too. Tests of electrical properties showed that implanted neurons behaved more similarly to cells that develop in human brains than cells grown in dishes.
Over months of growth, these human neurons made connections with their rat host cells. The human organoids were implanted in the somatosensory cortex, a part of the rat brain that handles whisker input. When researchers puffed air at the whiskers, some of the human cells responded.
What’s more, the human cells could influence the behavior of the rat. In further experiments, the researchers genetically tweaked the organoids to respond to blue light. Prompted by a flash of light, the neurons fired signals, and researchers rewarded the rats with water. Soon, the rats learned to move to the water spout when their human organoid cells sent signals.
In behavioral tests, rats with human implants didn’t show signs of higher intelligence or memory; in fact, researchers were more concerned with deficits. The human organoids were nudging out their hosts’ brains, after all. “Will there be memory deficits? Will there be motor deficits? Will there be seizures?” Pasca asked. But after extensive tests, including behavior tests, EEGs and MRIs, “we could not find differences,” Pasca says.
Other experiments included nerve cells from people with a genetic disorder called Timothy syndrome, a severe developmental disorder that affects brain growth. Growing organoids created with these patients’ cells in rats’ brains might reveal differences that other techniques would not, the researchers reasoned. Sure enough, neurons in these organoids had less complex message-receiving dendrites than those from organoids derived from people without the syndrome.
Organoids made from patient-specific cells could one day even serve as test subjects for treatments, Pasca says. “Challenging disorders will require bold approaches,” he says. “We will need to build human models that recapitulate more aspects of the human brain to study these uniquely human conditions.”
